Drug Topics June 18, 2024
Killian Meara

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses what the future looks like for psychedelic treatments.

The FDA’s Psychopharmacologic Drugs Advisory Committee voted against the use of MDMA to treat PTSD earlier this month, giving proponents of psychedelic treatments a disappointing setback. The panel, which raised various concerns about a new drug application from Lykos Therapeutics, was the first to review a psychedelic-assisted therapy in the United States. The panel’s decision has left many wondering what the future of psychedelic medicine now looks like.

Drug Topics sat down with Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, to discuss how the FDA advisory panel’s decision could impact the future of psychedelic medicine, if the decision...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, FDA, Govt Agencies, Interview / Q&A, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
FDA Clears Emerging Brain PET System
STAT+: Applesauce lead contamination could not have been prevented, top FDA official suggests
Trump’s FDA commissioner on regulating AI
FDA creates communication ‘super office’ at CDRH

Share This Article